found that combining MEK1/2 inhibition and VEGF-A inhibition led to synergistic inhibitory effects on tumor growth and angiogenesis in a mouse model of KRAS-mutant human non-small cell lung cancer [34]. Here, KRAS is linked to non-small cell lung carcinoma.